Federal authorities are accusing two top officials of CANARX, a Canadian prescription drug company, of running a long-running scheme to illegally import prescription drugs into the United States, according to court records filed Tuesday.

John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges, according to the records. His brother, Bob Howard, the company's president and a director, is also wanted in the investigation. He has not been taken into custody, according to an affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations.

The arrest warrant also charges John Thomas Howard with introducing misbranded drugs into interstate commerce and illegal drug importation. No plea has been filed.

The affidavit states that the FDA's investigation found "there is probable cause to believe that (CANARX) illegally imported or caused the illegal importation of prescription drugs into the United States." It does not specify which medications were involved. The complaint covers February 22, 2017, through April 15, 2026.

CANARX, founded in 2002 and based in Windsor, Ontario, describes itself as a prescription provider for U.S. patients and says it sources medications from Canada, the United Kingdom, Australia and New Zealand. Its general counsel, Joseph Morris, said in a statement: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court."

The FDA has scrutinized the company for several years. The agency seized medication CANARX was shipping in 2023, which it said was potentially misbranded and counterfeit. In 2019, it sent the company a warning letter saying CANARX was substituting FDA-approved drugs with unapproved drugs. Morris responded that the company was not misleading patients and agreed to stop importing drugs that must be administered by a doctor.

In a separate pending civil lawsuit, Gilead Sciences accused CANARX and other companies of illegally importing Biktarvy, its HIV medication. A Gilead spokesperson said the company "has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain." CANARX has not responded to the Gilead lawsuit.